Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Press Release – No. 4 / 2024
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024.
Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/ee4aippx. To receive telephone dial-in information and a unique personal access PIN, please register at https://register.vevent.com/register/BI3bf842a335dd49a79930cafce733506c. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand’s website at https://www.zealandpharma.com/events/.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contacts:
| Adam Lange (Investors) |
| Investor Relations Officer |
| Zealand Pharma |
| alange@zealandpharma.com |
| Anna Krassowska, PhD (Investors and Media) |
| Vice President, Investor Relations & Corporate Communications |
| Zealand Pharma |
| akrassowska@zealandpharma.com |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Start of construction work on the Uus-Kindrali20.5.2024 09:52:00 CEST | Press release
Start of construction work on the Uus-Kindrali Pro Kapital has started the construction of the next phase of the Kindrali Houses project in Tallinn Kristiine City. The building at Talli 3/Sammu 8, which is part of the Uus-Kindrali project, will comprise 90 apartments and one commercial unit. The new phase of Kindrali Houses will consist of a 7-storey building with 1-5 bedroom apartments. To date, 31% of the apartments have already been pre-sold, which was the incentive to start construction work. Uus-Kindrali, with its modern and Scandinavian architecture, will be built in Kristiine City and will be framed by a tree-lined avenue and Brooklyn-style high ground floor homes and commercial space opening directly onto the street. On the other side, between the buildings is a spacious and private courtyard with fruit trees, berry bushes, cozy seating and play areas, offering joy and activity for everyone. The architects of the buildings and landscape of the Uus-Kindrali is Allianss Arhitekti
Vaisala selected to deliver 18 weather radars to the State Meteorological Agency of Spain20.5.2024 09:15:00 CEST | Press release
Vaisala Press release May 20, 2024 Vaisala selected to deliver 18 weather radars to the State Meteorological Agency of Spain The new radars enhance the accuracy of weather data in Spain and the capability to predict extreme weather events, such as severe storms, in Southern Europe. The value of the project is approximately EUR 25 million, making it the largest-ever order for Vaisala. Vaisala, a global leader in measurement technology, has won the tendering of delivering a new weather radar system to the Spanish State Meteorological Agency (AEMET), which is an organization under the Ministry of Environment of the country (MITECO). The value of the project is approximately EUR 25 million, making it the largest single order for Vaisala ever. The contract will be signed after the public procurement appeal period has ended, and the order will be booked to Vaisala's orders received after the contract has been finalized. The contract includes 18 dual-polarization C-band weather radars (WRM200
Municipality Finance issues a EUR 75 million tap under its MTN programme20.5.2024 09:00:00 CEST | Press release
Municipality Finance Plc Stock exchange release 20 May 2024 at 10:00 am (EEST) Municipality Finance issues a EUR 75 million tap under its MTN programme On 21 May 2024 Municipality Finance Plc issues a new tranche in an amount of EUR 75 million to an existing benchmark issued on 26 April 2023. With the new tranche, the aggregate nominal amount of the benchmark is EUR 1.375 billion. The maturity date of the benchmark is 29 July 2030. The benchmark bears interest at a fixed rate of 3.125 % per annum. The new tranche is issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and final terms of the notes are available in English on the company's website at https://www.kuntarahoitus.fi/en/for-investors. MuniFin has applied for the new tranche to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 21 May 2024. The existing notes
DNA Plc: Changes in Executive Team20.5.2024 09:00:00 CEST | Press release
DNA PLC STOCK EXCHANGE RELEASE 20 MAY 2024 AT 10:00 DNA Plc’s SVP, Corporate Affairs (CCAO) and member of the Executive Team, Asta Rantanen, will retire effective 31 July. Master of Laws Vesa Vuoti has been appointed as her successor and member of DNA’s Executive Team as of 1 August. Vuoti has had a long career at DNA in a number of roles, most recently as VP, Legal and Regulatory Affairs. Previously, he has served as Director of Administration and Security, among others. Ph.D., CIO Sari Leppänen is appointed CTO for DNA. Since the beginning of May, she has temporarily managed that position alongside her own work after the previous CTO Ville Virtanen transferred to DNA’s parent company, Telenor. In addition to the new role, Leppänen will continue as the CIO for DNA. “I would like to thank Asta Rantanen for her great work at DNA over the past twenty years, first in several legal roles and later also as SVP of Corporate Affairs. Asta has developed DNA’s corporate governance policies rema
The subscription period for the warrants of series TO7 starts today, May 20, 202420.5.2024 08:30:00 CEST | Press release
Today, May 20, 2024, marks the commencement of the exercise period for subscription of warrants of series TO7 in Terranet AB (publ) (”Terranet” or the” Company”). The exercise period for warrants of series TO7 runs up until and including June 3, 2024. Each warrant gives the right to subscribe for one (1) new share of series B in the Company to the price of SEK 0.073 per share. The invested amount must be rounded up to two decimal places. For the warrants not to expire without value, the owner must actively subscribe for new shares no later than June 3, 2024, alternatively sell their warrants no later than May 29, 2024. Please observe that certain nominees might close their application period earlier than June 3, 2024. The letter to holders of warrants of series TO7 is available on the Company's website www.terranet.se. Summarized terms for the warrants of series TO7: Subscription period: May 20, 2024 – June 3, 2024. Issue size: 182,664,660 warrants of series TO7, which entitles to subs